The growing world of CAR T cell trials: a systematic review (Q38950791)

7 September 2017

1 reference

title

The growing world of CAR T cell trials: a systematic review (English)

1 reference

7 September 2017

1 reference

Astrid Holzinger

1

1 reference

7 September 2017

Markus Barden

series ordinal

2

1 reference

7 September 2017

Hinrich Abken

series ordinal

3

1 reference

7 September 2017

publication date

9 September 2016

1 reference

Cancer Immunology, Immunotherapy

7 September 2017

published in

1 reference

7 September 2017

volume

65

1 reference

7 September 2017

issue

12

1 reference

7 September 2017

page(s)

1433-1450

1 reference

The T-body approach: redirecting T cells with antibody specificity

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1895-5

10.1007/S00262-016-1895-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1016699577

0 references

1 reference